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Abstract
Aim: In cardiac arrest, ventricular fibrillation (VF) waveform analysis has identified the amplitude spectrum area (AMSA) as a key predictor of
defibrillation success and favorable neurologic survival. New resuscitation protocols are under investigation, where prompt defibrillation is restricted to
cases with a high AMSA. Appreciating the variability of in-field pad placement, we aimed to assess the impact of recording direction on AMSA-values,
and the inherent defibrillation advice.
Methods: Prospective VF-waveform study on 12-lead surface electrocardiograms (ECGs) obtained during defibrillation testing in ICD-recipients (2010
2017). AMSA-values (mVHz) of simultaneous VF-recordings were calculated and compared between all limb leads, with lead II as reference (proxy for
in-field pad position). AMSA-differences between leads I and II were quantified using Bland-Altman analysis. Moreover, we investigated differences
between these adjacent leads regarding classification into high (15.5), intermediate (6.515.5) or low (6.5) AMSA-values.
Results: In this cohort (n = 243), AMSA-values in lead II (10.2  4.8) differed significantly from the other limb leads (I: 8.0  3.4; III: 12.9  5.6, both p <
0.001). The AMSA-value in lead I was, on average, 2.24  4.3 lower than in lead II. Of the subjects with high AMSA-values in lead II, only 15% were
classified as high if based on assessments of lead I. For intermediate and low AMSA-values, concordances were 66% and 72% respectively.
Conclusions: ECG-recording direction markedly affects the result of VF-waveform analysis, with 2030% lower AMSA-values in lead I than in lead II.
Our data suggest that electrode positioning may significantly impact shock guidance by ‘smart defibrillators’, especially affecting the advice for prompt
defibrillation.
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Introduction
Ventricular fibrillation (VF) is the first observed cardiac rhythm in about
2030% of all out-of-hospital cardiac arrests (OHCAs).1,2 In an
attempt to improve outcomes, the potential value of VF-waveform
analysis is under active investigation.35
At present, the key VF-waveform characteristic is the amplitude
spectrum area (AMSA), a combined measure of VF amplitude and
frequency, containing predictive value for defibrillation success and
survival with favorable neurological outcome.4,68 AMSA correlates
with arrest duration and myocardial metabolic state and has been
shown to increase during high-quality cardiopulmonary resuscitation
(CPR).911 In that context, a current randomised trial compares
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defibrillation success between the conventional resuscitation protocol
and a strategy of defibrillation timing guided by real-time AMSA
assessment.5 In case of a high AMSA-value (15.5 mVHz) the
protocol directs immediate delivery of the first shock, while continua-
tion of chest compressions is indicated when AMSA is below 15.5
mVHz.
So-called “smart defibrillators” can automatically perform this real-
time analysis of the defibrillator electrocardiogram (ECG). Important-
ly, previous studies demonstrated that positioning of the defibrillator
electrodes may vary greatly in clinical practice.12,13 Such variations in
bipolar lead recordings could impact AMSA-measurements, which
has been suggested in a small surface ECG study.14 Depending on
the magnitude of this effect, this may impact the abovementioned
defibrillation guidance.
In this context, we performed an electrophysiologic study and
sought to quantify the impact of recording direction on VF-waveform
assessments, in a large series of patients with 12-lead surface ECGs.
First, we assessed whether and to what extent AMSA-values vary
between different ECG-leads, covering the total spectrum of AMSA
values, from low to high. Second, we assessed the impact of ECG
recording direction on classification into the currently defined
categories of AMSA-values for defibrillation guidance.4
Methods
Patient population
From our prospective registry of first implantable cardioverter
defibrillator (ICD) implantations at the Radboud University Medical
Center, we identified all patients with defibrillation testing between
20102017. From 2010 to 2013, defibrillation testing was routinely
performed in all patients, while in 20142017 this was only done for
specific indications. For the present analysis, we included all patients
with a standard 12-lead surface ECG of induced VF. Exclusion criteria
were: age <18 years, congenital heart disease and right-sided ICD
implants. Data on demographics, medical history and left ventricular
geometry were collected from patient records, as described
previously.15 Given the observational design of the study, written
informed consent was not necessary to obtain according to the Dutch
Act on Medical Research involving Human Subjects.
ICD implantation and testing
The devices implanted were Medtronic (Minneapolis, Minn, USA), St
Jude Medical (St. Paul, Minn, USA) or Biotronik (Berlin, Germany)
ICD, cardiac resynchronisation therapy-defibrillator systems with
transvenous single coil leads, or subcutaneous ICD-systems (s-ICDs,
Boston Scientific, Marlborough, MA, USA). An example of VF
induction and termination by an ICD shock is shown in Fig. 1.
Defibrillation testing was performed after ICD implantation to test the
ability of the implanted device to sense, detect and terminate VF
appropriately, according to our local hospital protocol. After sedation
with propofol, VF was induced using T-wave shock, direct current
pulses or 50 Hz burst pacing (in case of s-ICDs). The presence of VF
was confirmed on surface ECG recordings. Transvenous ICDs were
programmed to deliver three sequential shocks (15-25-35 Joule) until
VF was terminated, while s-ICDs were programmed to deliver two
sequential shocks (5065 Joule, according to the prevailing protocol
at the time of study). In case of persisting VF after the third
(transvenous devices) or second shock (s-ICDs), external defibrilla-
tion was performed.
VF waveform characteristics
Prior to defibrillation testing, a standard 12-lead surface ECG was
attached following standardised protocols, recorded with BARD
LabSystem (Lowell, Massachusetts, USA; sampling frequency 1000
Hz; 16-bit A/D converter). For each patient, we studied a single VF-
waveform segment prior to the first ICD shock given on VF.
All VF-waveform analyses were performed using Matlab (version
2018a, Mathworks, Natick, MA, USA). VF-signals were pre-proc-
essed with a 148 Hz bandpass filter. In concordance with the key
paper that studied threshold values of AMSA, we analysed VF-
Fig. 1 – The appearance of the ventricular fibrillation waveform (VF) in six different leads of the surface
electrocardiogram. First, VF is induced using a T-wave shock procedure. After about 10 s of VF, the arrhythmia is
terminated by an electrical shock of the ICD.
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segments of 2.05 s (2048 samples)4 Subsequently, the signal was
converted to the frequency domain using a fast Fourier transform.
From the amplitude frequency spectrum, AMSA was calculated as the
summed product of individual frequencies and their corresponding
amplitudes over an interval of 248 Hz, as described previously.15,16
Aims
The primary aim was to quantify the impact of ECG recording directions
on the value of AMSA, with particular interest for differences between
lead I and II. Analogous to previous studies, lead II was considered as a
proxy for the defibrillator ECG recording direction.1619
Secondly, we aimed to investigate whether and to what extent
ECG recording direction affected classification into the currently
prevailing AMSA-categories.4
Quantification of impact recording direction
First, we assessed AMSA-values for the bipolar limb leads,
augmented leads and precordial leads. Subsequently, we focused
on differences observed between lead I and lead II, representing a 608
difference in recording direction. Per subject, AMSA-differences
(AMSAdiff = AMSAlead I  AMSAlead II) and AMSA-means (AMSAmean
= (AMSAlead I + AMSAlead II)/2) were obtained from corresponding,
simultaneously recorded VF-segments of leads I and II, and Bland-
Altman analysis was performed.20 In the resulting scatter plots,
AMSAdiff is plotted against AMSAmean, providing an overview of the
magnitude of the observed differences over the total range of AMSA-
values.
Impact on classification into AMSA-categories
All AMSA-values obtained from VF-waveform calculations in lead I
and lead II were categorised, based on the three currently prevailing
AMSA-categories for defibrillation guidance: high (15.5 mVHz),
intermediate (6.515.5 mVHz) or low (6.5 mVHz).4,5 We assessed
whether classification differed with AMSA-values based on lead I
versus lead II.
Statistics
All statistical analyses were performed with IBM SPSS statistics
software (version 25, IBM Corp., Armonk, NY, USA). Categorical
variables were presented as numbers (percentages), continuous
variables were presented as means  standard deviations (SD).
Comparisons between AMSA-values in different leads were per-
formed using a one way repeated measures analysis of variance
(ANOVA). In case of significant differences, post-hoc pairwise
comparisons were performed using a paired t-test with Bonferroni
correction. To assess the level of agreement with regard to
classification into AMSA-categories, we used Cohen’s kappa. For
all analyses, a p-value of <0.05 was considered statistically significant.
Results
Patient characteristics
In total, we studied 243 patients with available ECG-recordings of
induced VF, of whom baseline characteristics are reported in Table 1.
The mean age was 63  13 years and 77% (186/243) was male. ICDs
were implanted for secondary prevention in 38% (92/243), 28% (68/
243) were CRT-D devices and 4% (9/243) were subcutaneous ICD-
systems. Forty-three percent (105/243) of all patients had a previous
myocardial infarction. Twelve percent (30/242) used amiodarone on a
daily basis and 89% (215/242) were treated with a beta blocker.
VF-waveform characteristics
AMSA-values: limb leads
Mean AMSA-values obtained from the limb leads of the surface ECG
are shown in Fig. 2a. The highest AMSA-values were found in lead III,
while the lowest AMSA-values were observed in lead I (12.9  5.5
mVHz vs 8.0  3.4 mVHz, paired t-test p < 0.001). The mean AMSA-
value in lead II was 10.2  4.8 mVHz, which was significantly different
from lead I and lead III (both pairwise tests p < 0.001).
AMSA-values: augmented limb leads
Mean AMSA-values obtained from the augmented leads of the
surface ECG are shown in Fig. 2b. The highest AMSA-values were
found in lead aVF, while the lowest AMSA-values were observed in
lead aVR (11.0  4.9 mVHz vs 6.6  2.9 mVHz, paired t-test p <
0.001).The mean AMSA-value in lead aVL was 9.5  3.9 mVHz,
which was significantly different from lead aVR and lead aVF (both
pairwise tests p < 0.001).
AMSA-values: precordial leads
Mean AMSA-values obtained from the precordial leads of the surface
ECG are shown in Fig. 2c. We observed significant differences
Table 1 – Baseline characteristics of study cohort with
surface ECG-recordings of VF.
Baseline characteristics
Age (yrs) 63  13
Male gender 186 (77)
Hypertension x 98 (41)
Diabetes x 54 (22)
Atrial fibrillation x 70 (29)
History of myocardial infarction x 105 (43)
Secondary prevention 92 (38)
CRT-D 68 (28)
Subcutaneous ICD 9 (4)
BSA (m2) xx 2.0  0.2
LV ejection fraction (%) y 37  14
LV internal diastolic diameter index (cm/m2) yy 3.0  0.5
QRS duration (ms) { 122  28
Beta blocker x 215 (89)
Amiodarone x 30 (12)
Values are reported as n (%), means  standard deviations or medians
(interquartile ranges), whichever appropriate. BSA: body surface area,
CRT-D: cardiac resynchronisation therapy-defibrillator, ECG: electrocar-
diogram, ICD: implantable cardioverter defibrillator; LV: left ventricular; VF:
ventricular fibrillation.
x Derived from N = 242 patients.
xxDerived from N = 195 patients.
y Derived from N = 164 patients.
yyDerived from N = 189 patients.
{ Derived from N = 193 patients.
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between AMSA-values of the precordial leads (ANOVA p < 0.001).
The highest AMSA-values were found in lead V3 and the lowest in lead
V1 (20.5  9.6 mVHz vs. 10.0  4.7 mVHz, pairwise t-test p < 0.001).
Significant differences were found between all precordial leads (all p <
0.001), except for lead pairs V1-V6 (p = 0.08) and V2V3 (p = 0.52).
Impact of recording direction: Lead I vs. Lead II
Fig. 3a shows the Bland-Altman plot of AMSA-values of ECG-leads I
(AMSAI) and II (AMSAII). The difference in AMSA between leads I and
II (AMSAI  AMSAII) was 2.24  4.3 mVHz, corresponding to a
relative difference between these leads of 22%. Absolute and
relative differences between AMSA-values of lead I and lead II varied
per AMSA-category (Fig. 3 bd). In case of a low AMSA in lead II
(6.5 mVHz), the mean AMSA was slightly higher in lead I than in lead
II (0.4  1.9 mVHz, +8%). For the intermediate and high AMSAII
values, the mean AMSA was lower in lead I than in lead II. In case of an
intermediate AMSAII (6.515.5 mVHz) the difference in AMSA was
1.8  3.3 mVHz (18%). In case of a high AMSAII (15.5 mVHz),
the highest absolute and relative differences were found: 8.8  5.2
mVHz (44%).
Impact on classification into AMSA-categories
Of the 243 AMSA-values obtained from lead II, 53 (22%) were
classified into the low, 157 (65%) into the intermediate and 33 (13%)
into the high AMSA-category (Fig. 4).
Of the 33 patients with a high AMSA in lead II, 15% had a
corresponding high AMSA when calculated from lead I, while 85% was
classified as either intermediate (67%) or low AMSA (18%).
Of the 157 patients with an intermediate AMSA in lead II, 66% was
also classified as intermediate with data from lead I. For the 53 patients
with a low AMSA in lead II, 72% was also classified as low with data
from lead I, Cohen’s kappa = 0.27.
Discussion
In follow-up on VF-waveform studies that reported on shock success
prediction4,21 and clinical studies demonstrating the prognostic value
of VF-waveform analysis,3,22 this experimental study was undertaken
to provide additional information that may contribute to the further
logistic development and optimal application of this promising
Fig. 2 – (a) AMSA of limb leads (means + standard deviation). Significant differences were found between AMSA-values
(ANOVA p < 0.001). Post-hoc pairwise comparisons revealed significant differences between all lead pairs (all t-tests p
< 0.001, p-for-significance after Bonferroni correction = 0.017). (b) AMSA of augmented leads (means + standard
deviation). Significant differences were found between AMSA-values (ANOVA p < 0.001). Post-hoc pairwise
comparisons revealed significant differences between all lead pairs (all t-tests p < 0.001, p-for-significance after
Bonferroni correction = 0.017). (c) AMSA of precordial leads (means + standard deviation). Significant differences
were found between AMSA-values (ANOVA p < 0.001). Post-hoc pairwise comparisons revealed significant differences
between all lead pairs, except from V1-V6 and V2-V3 (all other t-tests p < 0.001, p-for-significance after Bonferroni
correction = 0.008).
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technology. In this large series, we quantified the impact of ECG
recording direction on AMSA over its entire spectrum of values. In
relative terms, AMSA differed 2030% when recorded in a more
horizontal direction, with an absolute 2.2 mVHz lower mean AMSA
value in lead I than in lead II. Translated to clinical practice during
OHCA, calculation of absolute AMSA-values by a smart defibrillator
will be subject to electrode placement, resulting in a VF-guided
defibrillation advice that will less likely direct towards immediate
defibrillation, in case pads are placed more horizontally.
AMSA and cardiac arrest
In cardiac arrest, AMSA correlates with arrest duration and myocardial
metabolic state.9,18 This has been regarded the underlying mecha-
nism for AMSA to have moderate to good predictive ability for
defibrillation success and favorable neurological outcome.4,6,7
Of the potential applications of VF-waveform analysis, shock
success prediction has been investigated most extensively.2328 In a
large OHCA-cohort, threshold values for AMSA to predict shock
success have been derived, with classification of AMSA as either low
(6.5 mVHz), intermediate (6.515.5 mVHz) or high (15.5
mVHz).4,5 Currently, a randomised trial investigates a new resuscita-
tion protocol, based on real-time AMSA analysis by a ‘smart
defibrillator’. Shock success with the new resuscitation protocol will
be compared to that achieved with a standard CPR-protocol. In the
new protocol, prompt defibrillation is only performed when AMSA is
high, while the first shock is postponed for additional chest
compressions if AMSA is classified as intermediate or low. Moreover,
if AMSA reaches a value above 15.5 mVHz during subsequent 2-
minute CPR-cycles, the protocol directs immediate defibrillation as
well.
In the context of such new resuscitation protocols, applying cut-off
values for AMSA, it is a key aspect to study reproducibility of AMSA-
measurements. From studies with both laypersons and professionals
it is known that pad misplacement is common in clinical practice,
resulting in variations in bipolar lead recording.12,13,2931 In a previous
Fig. 3 – Bland-Altman plots of amplitude spectrum area (AMSA) values, simultaneously acquired by surface ECG lead I
and lead II. Figure a: total population; Figure b: patients with a low AMSA in lead II (6.5 mVHz); Figure c: patients with
an intermediate AMSA in lead II (6.515.5 mVHz); Figure d: patients with a high AMSA in lead II (15.5 mVHz).
Fig. 4 – Categorization of AMSA-values when using VF-waveform information of lead I, compared to lead II. AMSA in lead
II (mVHz) is categorised as ‘low’ (6.5, N=53), ‘intermediate’ (6.515.5, N=157) or high (15.5, N=33).
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investigation on the correctness of pad placement in a sample of 136
health care professionals whose duty was to perform defibrillation,
only 25% of the subjects attached both pads within 5 cm of the
proposed range.31 Although misplacement was not further defined in
terms of absolute angles, it was shown that pads were predominantly
placed either too low (sternal pad) or too medial (apical pad), but
variations were present in both vertical as well as horizontal directions.
A previous small study (n = 45) already suggested that such variations
in recording direction could impact amplitude and frequency related
VF-measures.14
In this larger patient series we now provide a quantitative
estimation of how AMSA-values differ in relation to recording direction,
and we studied this aspect over a wide range of values, also including
ECG-leads in the transverse plane. On average, we found absolute
AMSA-values to be markedly lower in lead I than in lead II (2.2  4.3
mVHz), with less pronounced differences in lower, and marked
differences in higher AMSA values. While AMSA-values were
observed to be almost equal in the low category (6.5 mVHz,
absolute difference 0.4 mVHz, +8%), AMSA in lead I was markedly
lower than in lead II in the high category (15.5 mVHz, absolute
difference 8.8 mVHz, 44%). In relative terms, the observed
average difference between lead I and lead II was 22%, which
corroborates with the about 30% difference as reported previously.14
AMSA-measurements in the transverse plane resulted in clearly
higher values than in the coronal plane, which may be related to the
fact that leads are located much closer to the myocardial wall.
Translating these experimental findings into potential consequen-
ces in the field, we applied our findings to the currently used protocol of
so-called ‘smart defibrillators’ during OHCA. In this protocol, prompt
delivery of the first shock is advised in case of a high AMSA of 15.5
mVHz.5
We showed that 85% of the high AMSA-values based on lead II are
classified as either ‘intermediate’ or ‘low’ based on lead I. This
classification difference shows the marked clinical impact of a more
horizontal recording direction, resulting in a lower likelihood that a
prompt first defibrillation will be advised. Moreover, in the AMSA-trial,
the VF-guided defibrillation threshold of 15.5 mVHz is not restricted to
the first, but applies to all shocks, and the placement issue therefore
has implications for all subsequent CPR-cycles throughout the
resuscitation attempt.
Implications
The findings of our study provide important information for future
directions of new resuscitation protocols with smart defibrillators. The
key rationale of such protocols is that a high AMSA is associated with a
high chance of shock success. Although the hypothesis to perform
early defibrillation in these patients and postpone defibrillations in
others may be right, incorrect pad placement may affect AMSA-
values. In turn, this may have implications for shock advice, which may
ultimately impact trial outcomes. Our current findings may be of value
to interpret trial outcomes in a more comprehensive context and
provide an explanation why negative studies on such protocols may
not necessarily mean that the initial concept can be refuted.
Moreover, from an electrophysiological point of view, this is one of
the largest studies on 12-lead VF registrations, providing detailed
information on the VF-waveform in various recording directions. This
information may contribute to future initiatives with a study design to
specifically unravel the quantitative association between recording
direction and AMSA assessment, as this may potentially contribute to
further refinement of existing algorithms. We observed the highest
AMSA-value in lead III of the coronal plane, and in lead V3 of the
transverse plane. The fact that AMSA differs across limb leads,
suggests that the locality of the VF rotors may contribute to the
appearance of the VF-waveform in a certain direction.
Previously, we demonstrated that the presence or absence of prior
infarction also affects the VF-waveform, and that AMSA values are
lower in the leads adjacent to the area of infarction.15 In patients
without infarction myocardial mass is another factor that plays a role.32
Additional OHCA-studies are warranted to further explore all
different aspects involved that potentially affect VF-waveform
measurements with smart defibrillators in the OHCA situation.33
Limitations
In terms of inferences to the OHCA-setting, our data reflect early,
induced VF. This may limit the generalizability of the observed
magnitude of the absolute differences, but the direction of the
observed differences will not change. In addition, we studied surface
ECG-recordings, and not defibrillator pad registrations. However,
from an electrophysiological point of view, the used limb lead
registrations are bipolar, just like defibrillator ECG-registrations, which
makes it reasonable to assume that the observed differences apply to
other devices and in-field VF as well.
Although we calculated AMSA-values in concordance with the key
paper on this topic,4 technical aspects (e.g. built-in device and filter
settings) may have influenced absolute AMSA-values in this study.
Yet, for our current study question, addressing within-patient differ-
ences between lead I and lead II, this does not affect the main
conclusions.
Lastly, we studied the population of ICD-recipients as a whole, and
did not stratify our analyses according to underlying cardiac disease.
In sub-analyses on the effect of recording direction between patients
with and without a previous myocardial infarction, we found uniform
results in both subsets.
Conclusion
In this conceptual VF-waveform study with 12-lead surface ECG-
recordings, we demonstrate that AMSA-values are markedly affected
by ECG recording direction, with values that are lower in lead I than in
lead II, in relative terms 2030%. Appreciating the variability in pad
placement during cardiac arrest, our findings indicate that a more
horizontal recording direction leads to lower AMSA-values. For
studies on new resuscitation protocols with ‘smart defibrillators’, this
implies that the corresponding VF-guided defibrillation will less likely
direct towards prompt administration of the first shock. In an era of
studies on AMSA-guided defibrillation timing, our findings highlight
important aspects for the full interpretation of such trials and may
provide new directions for the optimal implementation of 'smart
defibrillators' in the setting of out-of-hospital cardiac arrest.
CRediT authorship contribution statement
Jos Thannhauser: Conception and design, Collection and assembly
of data, Analysis and interpretation of data, Drafting of the manuscript,
6 R E S U S C I T A T I O N P L U S 6 ( 2 0 2 1 ) 1 0 0 1 1 4
Final approval of the manuscript. Joris Nas: Conception and design,
Analysis and interpretation of data, Drafting of the manuscript, Final
approval of the manuscript. Priya Vart: Analysis and interpretation of
data, Critical revising, Final approval of the manuscript. Joep L.R.M.
Smeets: Collection and assembly of data, Critical revising, Final
approval of the manuscript. Menko-Jan de Boer: Collection and
assembly of data, Critical revising, Final approval of the manuscript.
Niels van Royen: Analysis and interpretation of data, Critical revising,
Final approval of the manuscript. Judith L. Bonnes: Conception and
design, Collection and assembly of data, Analysis and interpretation of
data, Critical revising, Final approval of the manuscript. Marc A.
Brouwer: Conception and design, Analysis and interpretation of data,
Drafting of the manuscript, Final approval of the manuscript.
The manuscript has not been published and is not being
considered for publication elsewhere in whole or in part in any
language. All authors have read and approved the manuscript.
Conflicts of interest
Prof. de Boer is a member of the European advisory board on
interventional cardiology of Medtronic. Prof. van Royen received
research grants from Abbott, Biotronik, AstraZeneca and Philips, and
professional fees from Abbott and Medtronic. The other authors have
no conflicts of interest to declare.
Acknowledgements
None.
R E F E R E N C E S
1. Berdowski J, Berg RA, Tijssen JG, Koster RW. Global incidences of
out-of-hospital cardiac arrest and survival rates: Systematic review of
67 prospective studies. Resuscitation 2010;81:147987.
2. Kiguchi T, Okubo M, Nishiyama C, et al. Out-of-hospital cardiac arrest
across the World: First report from the International Liaison Committee
on Resuscitation (ILCOR). Resuscitation 2020;152:3949.
3. Indik JH, Conover Z, McGovern M, et al. Association of amplitude
spectral area of the ventricular fibrillation waveform with survival of out-
of-hospital ventricular fibrillation cardiac arrest. J Am Coll Cardiol
2014;64:13629.
4. Ristagno G, Mauri T, Cesana G, et al. Amplitude spectrum area to
guide defibrillation: a validation on 1617 patients with ventricular
fibrillation. Circulation 2015;131:47887.
5. Ristagno G., Latini R. Real Time Amplitude Spectrum Area to Guide
Defibrillation. ClinicalTrials.gov [Internet]. Identifier: NCT03237910;
2017 Aug 3 [cited 2020 Aug 12] Available from: https://ClinicalTrials.
gov/show/NCT03237910.
6. Indik JH, Conover Z, McGovern M, et al. Amplitude-spectral area and
chest compression release velocity independently predict hospital
discharge and good neurological outcome in ventricular fibrillation out-
of-hospital cardiac arrest. Resuscitation 2015;92:1228.
7. Schoene P, Coult J, Murphy L, et al. Course of quantitative ventricular
fibrillation waveform measure and outcome following out-of-hospital
cardiac arrest. Heart Rhythm 2014;11:2306.
8. Coult J, Kwok H, Sherman L, Blackwood J, Kudenchuk PJ, Rea TD.
Ventricular fibrillation waveform measures combined with prior shock
outcome predict defibrillation success during cardiopulmonary
resuscitation. J Electrocardiol 2018;51:99106.
9. Salcido DD, Menegazzi JJ, Suffoletto BP, Logue ES, Sherman LD.
Association of intramyocardial high energy phosphate
concentrations with quantitative measures of the ventricular
fibrillation electrocardiogram waveform. Resuscitation 2009;80:946
50.
10. Eftestol T, Wik L, Sunde K, Steen PA. Effects of cardiopulmonary
resuscitation on predictors of ventricular fibrillation defibrillation
success during out-of-hospital cardiac arrest. Circulation 2004;110:10
5.
11. Thannhauser J, Nas J, van Grunsven PM, et al. The ventricular
fibrillation waveform in relation to shock success in early vs. late
phases of out-of-hospital resuscitation. Resuscitation 2019;139:99
105.
12. Heames RM, Sado D, Deakin CD. Do doctors position defibrillation
paddles correctly? Observational study. BMJ 2001;322:13934.
13. Bodtker H, Rosendahl D. Correct AED electrode placement is rarely
achieved by laypersons when attaching AED electrodes to a human
thorax. Resuscitation 2018;127:e123.
14. Indik JH, Peters CM, Donnerstein RL, Ott P, Kern KB, Berg RA.
Direction of signal recording affects waveform characteristics of
ventricular fibrillation in humans undergoing defibrillation testing
during ICD implantation. Resuscitation 2008;78:3845.
15. Bonnes JL, Keuper W, Westra SW, et al. Characteristics of ventricular
fibrillation in relation to cardiac aetiology and shock success: A
waveform analysis study in ICD-patients. Resuscitation 2015;86:95
9.
16. Thannhauser J, Nas J, Rebergen DJ, et al. Computerized analysis of
the ventricular fibrillation waveform allows identification of myocardial
infarction: A proof-of-concept study for smart defibrillator applications
in cardiac arrest. J Am Heart Assoc 2020;9:e016727.
17. Gundersen K, Kvaløy JT, Kramer-Johansen J, Steen PA, Eftestøl T.
Development of the probability of return of spontaneous circulation in
intervals without chest compressions during out-of-hospital cardiac
arrest: an observational study. BMC Med 2009;7:6.
18. Gazmuri RJ, Kaufman CL, Baetiong A, Radhakrishnan J. Ventricular
fibrillation waveform changes during controlled coronary perfusion
using extracorporeal circulation in a Swine model. PLoS One 2016;11:
e0161166.
19. Indik JH, Hilwig RW, Zuercher M, Kern KB, Berg MD, Berg RA.
Preshock cardiopulmonary resuscitation worsens outcome from
circulatory phase ventricular fibrillation with acute coronary artery
obstruction in swine. Circ Arrhythm Electrophysiol 2009;2:17984.
20. Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986;1:307
10.
21. Nakagawa Y, Amino M, Inokuchi S, Hayashi S, Wakabayashi T, Noda
T. Novel CPR system that predicts return of spontaneous circulation
from amplitude spectral area before electric shock in ventricular
fibrillation. Resuscitation 2017;113:812.
22. Hulleman M, Salcido DD, Menegazzi JJ, et al. Predictive value of
amplitude spectrum area of ventricular fibrillation waveform in patients
with acute or previous myocardial infarction in out-of-hospital cardiac
arrest. Resuscitation 2017;120:12531.
23. Povoas HP, Bisera J. Electrocardiographic waveform analysis for
predicting the success of defibrillation. Crit Care Med 2000;28:N210
1.
24. Marn-Pernat A, Weil MH, Tang WC, Pernat A, Bisera J. Optimizing
timing of ventricular defibrillation. Crit Care Med 2001;29:23605.
25. Nakagawa Y, Sato Y, Kojima T, et al. Amplitude spectral area:
Predicting the success of electric shock delivered by defibrillators with
different waveforms. Tokai J Exp Clin Med 2013;38:716.
26. Coult J, Sherman L, Kwok H, Blackwood J, Kudenchuk PJ, Rea TD.
Short ECG segments predict defibrillation outcome using quantitative
waveform measures. Resuscitation 2016;109:1620.
27. Freese JP, Jorgenson DB, Liu PY, et al. Waveform analysis-guided
treatment versus a standard shock-first protocol for the treatment of
out-of-hospital cardiac arrest presenting in ventricular fibrillation:
R E S U S C I T A T I O N P L U S 6 ( 2 0 2 1 ) 1 0 0 1 1 4 7
results of an international randomized, controlled trial. Circulation
2013;128:9951002.
28. Ristagno G, Li Y, Fumagalli F, Finzi A, Quan W. Amplitude spectrum
area to guide resuscitation-a retrospective analysis during out-of-
hospital cardiopulmonary resuscitation in 609 patients with ventricular
fibrillation cardiac arrest. Resuscitation 2013;84:1697703.
29. Foster AG, Deakin CD. Accuracy of instructional diagrams for
automated external defibrillator pad positioning. Resuscitation
2019;139:2828.
30. Nurmi J, Castren M. Layperson positioning of defibrillation electrodes
guided by pictorial instructions. Resuscitation 2005;64:17780.
31. Nurmi J, Rosenberg P, Castren M. Adherence to guidelines when
positioning the defibrillation electrodes. Resuscitation 2004;61:143
7.
32. Bonnes JL, Thannhauser J, Nas J, et al. Ventricular fibrillation
waveform characteristics of the surface ECG: Impact of the left
ventricular diameter and mass. Resuscitation 2017;115:829.
33. Hulleman M, Salcido DD, Menegazzi JJ, et al. Ventricular fibrillation
waveform characteristics in out-of-hospital cardiac arrest and
cardiovascular medication use. Resuscitation 2020;151:17380.
8 R E S U S C I T A T I O N P L U S 6 ( 2 0 2 1 ) 1 0 0 1 1 4
